What are the indications for tirzepatide (GLP‑1 receptor agonist)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

FDA-Approved Indications for Tirzepatide

Tirzepatide is FDA-approved for three primary indications: type 2 diabetes mellitus (approved 2022), obesity (approved 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (approved December 2024). 1

Primary FDA-Approved Indications

1. Type 2 Diabetes Mellitus

Tirzepatide received FDA approval in May 2022 for glycemic control in adults with type 2 diabetes at doses of 5 mg, 10 mg, and 15 mg weekly 2. The SURPASS trials demonstrated:

  • HbA1c reduction of 1.9% to 2.58% with >87% of patients reaching HbA1c target of <7% 1
  • In SURMOUNT-2 (patients with both T2DM and obesity), tirzepatide achieved 2.2% A1C reduction with nearly half of participants reaching normal A1C values (<5.7%) 1
  • Superior efficacy compared to basal insulin, with uncommon episodes of level 2 hypoglycemia and no level 3 hypoglycemia 1

Tirzepatide is particularly recommended as a preferred first-choice medication for patients with both T2DM and obesity due to its dual benefits on glycemic control and substantial weight reduction 2.

2. Obesity

FDA approved tirzepatide in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity 3. The SURMOUNT trials demonstrated unprecedented weight loss:

  • SURMOUNT-1: 22.5% average weight reduction at 72 weeks with 15 mg dose, with nearly 40% of participants losing ≥25% of body weight 1
  • SURMOUNT-3 and SURMOUNT-4: Weight reduction up to 26.6% and 26% respectively when combined with intensive lifestyle intervention or continued treatment 1
  • Superior to GLP-1 receptor agonists: Meta-analysis showed tirzepatide 15 mg weekly produced 5.1% greater weight loss than semaglutide 2.4 mg weekly 3

3. Obstructive Sleep Apnea

In December 2024, tirzepatide became the first prescription medication FDA-approved specifically for moderate-to-severe OSA in adults with obesity 1. This represents a significant expansion beyond traditional CPAP-based management.

Clinical Positioning and Decision-Making

For Type 2 Diabetes Patients:

  • With obesity: Tirzepatide is the preferred first choice over standard GLP-1 receptor agonists due to superior weight loss (15-20% vs 5-10%) 2
  • At higher cardiovascular/kidney risk: Decision-making requires nuance. While GLP-1 receptor agonists have established cardiovascular and kidney benefits with high certainty evidence, tirzepatide offers superior weight loss but currently uncertain cardiovascular benefits 4
  • If replacing a GLP-1 RA with tirzepatide in high-risk patients, initiation or continuation of an SGLT-2 inhibitor is indicated to maintain cardiovascular and kidney protection 4

For Obesity Patients:

  • Lower cardiovascular/kidney risk: Most patients are anticipated to choose tirzepatide over GLP-1 receptor agonists given superior weight loss effects 4
  • Moderate to higher cardiovascular/kidney risk: Weigh the higher certainty of cardiovascular and kidney benefits (offered by GLP-1 receptor agonists) against larger weight loss benefits (offered by tirzepatide) 4
  • The large reduction in body weight (mean 8.63 kg; moderate certainty evidence) must be balanced against uncertainties regarding cardiovascular and kidney outcomes (generally low or very low certainty evidence) 4

Emerging and Investigational Indications

Beyond FDA-approved uses, tirzepatide has demonstrated benefits in:

  • Prevention of prediabetes progression to T2DM 1
  • Heart failure with preserved ejection fraction (HFpEF) amelioration 1
  • Metabolic dysfunction-associated steatohepatitis (MASH): Improvement in histology and fibrosis 1
  • Osteoarthritis symptom improvement 1

Important Caveats and Contraindications

Do NOT combine with:

  • GLP-1 receptor agonists (redundant mechanism) 4

CAN be combined with:

  • SGLT-2 inhibitors (complementary mechanisms, especially important for cardiovascular/kidney protection) 4
  • Finerenone 4

Contraindications:

  • Personal or family history of medullary thyroid cancer 2
  • Multiple endocrine neoplasia syndrome type 2 2

Common Adverse Effects:

  • Gastrointestinal symptoms (nausea in 25%, vomiting and diarrhea in up to 10%) occurring most commonly during dose escalation 1, 2
  • Increased risk of gallbladder or biliary disease 2
  • Moderate certainty evidence for severe gastrointestinal events 4

Dosing

Tirzepatide is formulated as once-weekly subcutaneous injection (half-life 116.7 hours), titrated monthly from starting dose of 2.5 mg weekly to maximum dose of 15 mg weekly 1. FDA-approved maintenance doses are 5,10, and 15 mg per week.

Ongoing Evidence

  • SURPASS-CVOT: Ongoing cardiovascular outcomes trial in patients with T2DM 1, 2
  • SURMOUNT-MMO: Ongoing cardiovascular outcomes trial investigating primary and secondary CV risk prevention in individuals with obesity without diabetes 1

The panel acknowledged that recommendations for tirzepatide may require updating as more evidence accumulates regarding cardiovascular and kidney-related complications 4.

References

1
Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Related Questions

How do GLP‑1 receptor agonists compare to dual GLP‑1/GIP receptor agonists (e.g., tirzepatide) for treating type 2 diabetes or obesity?
What is the recommended management for patients who are resistant to tirzepatide (dual GIP/GLP‑1 receptor agonist)?
For a 72-year-old male with type 2 diabetes and obesity who is on tirzepatide (Mounjaro) 5 mg weekly and glipizide extended‑release 5 mg daily, what are the recommended management steps?
Can a patient with type 2 diabetes mellitus take glipizide, pioglitazone, and Mounjaro (tirzepatide) together?
In a 38‑year‑old man with type 2 diabetes, hypertension, hyperlipidemia, and morbid obesity (weight 340 lb, BMI ≈ 56.7), whose HbA1c has risen from 6.8 % to 9.1 % over three months and who does not self‑monitor glucose, and who is currently taking tirzepatide (Mounjaro) 7.5 mg subcutaneously weekly, insulin glargine (Lantus) 26 units subcutaneously nightly, and metformin 1000 mg twice daily, what medication adjustments are indicated?
What fluoroquinolone ear preparations are available for an adult patient with an intact tympanic membrane to treat acute otitis externa?
What delivery method does the American College of Obstetricians and Gynecologists (ACOG) recommend for a pregnant patient with chronic hypertension that is well controlled on labetalol?
Is bisoprolol primarily water‑soluble or lipid‑soluble?
How should I manage a patient who develops a persistent metallic taste in the mouth after initiating statin therapy?
How can I explain sodium bicarbonate therapy to a patient, including its mechanism, dosing, administration, and potential side effects?
In a patient with suspected normal‑pressure hydrocephalus, how long does the removed cerebrospinal fluid re‑accumulate after a lumbar puncture?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.